Barry, OppHub America Desk · · Source: yahoo-tickers-tape-movers
Eli Lilly Raises 2026 Revenue Forecast by $5.5 Billion
Housing & mortgages: Rate and housing policy spill into builders, small-caps, and REITs.
Based on reporting from yahoo-tickers-tape-movers.
Eli Lilly raised its 2026 revenue forecast by $5.5 billion following robust third-quarter results, driven by strong growth in its pharmaceutical portfolio. Investors are weighing valuation concerns after a 57% run-up over the past 52 weeks against accelerating sales in products like Zepbound and Mounjaro.
Market context for this story
As of: WeekendLoading quotes…
Informational only — not investment advice. Full markets →
$SPYSPDR S&P 500 ETF
TradingView
Live chart & market data via TradingView · OppHub classroom · Delayed or exchange real-time per TradingView data agreements · Not investment advice
Educational TradingView chart — search any symbol in the widget. Confirm on /markets/SPY. Not investment advice.
Related markets
Shares a vertical MP4 loop to your phone's camera roll or app share sheet (Instagram, TikTok, Facebook Reels).
### Session Tape - S&P 500: 7,376.86 (+0.3%) - DJI: 51,285.73 (-0.5%) - NASDAQ: 24,579.42 (+1.1%) - Bitcoin: $75,762.00 (-0.1%)
## Catalyst Analysis: Guidance and Revenue Expansion Eli Lilly reported third-quarter revenue of $24.4 billion, representing a 39% increase compared to the same period a year ago. Earnings per share rose 16% to $7.22 in the quarter. Growth was anchored by surging demand across key treatments, with Zepbound sales climbing to $2.4 billion and Mounjaro sales advancing 65% to exceed $10.7 billion. Alongside these metrics, management lifted the 2026 revenue forecast by $5.5 billion. However, market participants continue to assess valuation multiples following a 57% run-up over the preceding 52 weeks, raising questions regarding future margin expansion and sustainability.
Read the full story
Original reporting and related coverage — attribution links only, not paid recommendations.
Trade this story
Robinhood
Webull
Tradier
IBKR
Chart this story
TradingView
Broker and exchange buttons use invite / refer-a-friend links (rewards may be capped). Charting links (TradingView) are partner offers that may pay OppHub America a commission at no extra cost to you.
OppSHOP
Full OppSHOP →As an Amazon Associate, OppHub America earns from qualifying purchases. Shopping here helps keep the site free — at no extra cost to you. Disclosure
OppSHOP
Related to this story
Housing & mortgages: Rate and housing policy spill into builders, small-
Shop related →
Investing books
Read the classics
Shop this pick →
Personal finance books
Run the household books
Shop this pick →
Trading notebooks
Write the thesis first
Shop this pick →
Monitor for charts
See every pane
Shop this pick →
Story playbook
A pre-built map of what to watch — stocks, ETFs, and educational next steps. Not personalized advice.
Snapshot date: November 7, 2026 at 2:01 PM ET
This playbook was built when the story published and is not live-updated. Prices, news, and risk can change after this date — treat it as a starting map, not a current trade ticket.
Story → money map
biotech pharma growth
Drugmaker Eli Lilly announced much higher future sales expectations because its popular weight-loss and diabetes treatments are selling extremely fast. Investors care because even though the company is growing rapidly, its stock price has already risen a lot, leading some to worry it might be overpriced.
What changed
Eli Lilly raised its 2026 revenue forecast by $5.5 billion following strong third-quarter sales of Zepbound and Mounjaro.
Who wins / who loses
Pharmaceutical firms leading in weight-loss treatments benefit from high demand, while higher-valued names face valuation scrutiny.
Time horizon
Think in terms of the next few months.
Confidence & best fit
high confidence · Long-term investor, Active trader
Safer theme exposure (ETFs)
Baskets that own the theme without betting on one company.
Single stocks (higher risk)
Primary = closest to the story · Peers = same industry · Second-order = knock-on effects · Avoid = looks related but may be a trap
Primary
- $LLYWatch — track, don’t rush
The main company in the news is growing fast due to popular new medications, but investors are watching the high stock price.
View $LLY chart → · End-of-day delayed data
Peer
- $NVOBuild slowly — only if it fits your plan
Eli Lilly's main rival in diet drugs, which also stands to benefit as more people buy these treatments.
View $NVO chart → · End-of-day delayed data
Options (education only)
No strikes or expiries — a framework for how traders might express the view. Options can expire worthless.
Direction: bullish · Style: Debit spread (defined risk) · Level: intermediate
Beginners should skip options here due to high stock volatility and expensive premiums after a massive 57% run-up.
Income / OppHub America angle
Not a trade tip — ways to use the insight outside the market.
- Local healthcare providers and specialized clinics seeing increased patient traffic for lifestyle and weight management consultations.
What would break this thesis
- Unexpected supply chain constraints limiting drug manufacturing output or a sudden deceleration in quarterly prescription growth.
What to do next on OppHub America
Saved playbooks stay on this device for now.
Important
Not financial advice. OppHub America playbooks are educational market maps only — not recommendations to buy, sell, or hold any security. Markets move fast; information can be wrong or outdated. Trade and invest at your own risk. Do your own research or consult a licensed advisor.
Based on reporting from yahoo-tickers-tape-movers.
Informational and educational only — not investment, financial, or legal advice. Disclosure
Shares a vertical MP4 loop to your phone's camera roll or app share sheet (Instagram, TikTok, Facebook Reels).